We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Ibrutinib in relapsed hairy cell leukemia variant: A case report and review of the literature.
- Authors
Visentin, Andrea; Imbergamo, Silvia; Trimarco, Valentina; Pravato, Stefano; Romano Gargarella, Leila; Frezzato, Federica; Scapinello, Greta; Bertorelle, Roberta; Piva, Elisa; Facco, Monica; Semenzato, Gianpietro; Piazza, Francesco; Trentin, Livio
- Abstract
Hairy cell leukemia variant (HCLv) is a provisional disease in the 2016 WHO classification of lymphomas, characterized by unfavorable prognosis and early relapse following conventional purine analog‐based regimens. In this study, we report 2 patients with relapsed HCLv treated with ibrutinib. The first patient achieved a partial response following ibrutinib treatment and received the drug for 16 months, without severe adverse events. However, at disease progression venetoclax was not clinically active. The second patient discontinued the drug early due to intolerance. Ibrutinib was active in our patients with HCLv and deserve further investigations.
- Subjects
LITERATURE reviews; LEUKEMIA; DISEASE progression; CELLS; LYMPHOMAS
- Publication
Hematological Oncology, 2020, Vol 38, Issue 5, p823
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.2810